Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Non-Current Deferred Tax Liability (2018 - 2025)

OptimizeRx (OPRX) has disclosed Non-Current Deferred Tax Liability for 8 consecutive years, with $10.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability rose 139.5% to $10.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.8 million through Dec 2025, up 139.5% year-over-year, with the annual reading at $10.8 million for FY2025, 139.5% up from the prior year.
  • Non-Current Deferred Tax Liability hit $10.8 million in Q4 2025 for OptimizeRx, up from $4.5 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $10.8 million in Q4 2025 to a low of $2.3 million in Q4 2022.
  • Historically, Non-Current Deferred Tax Liability has averaged $4.3 million across 5 years, with a median of $4.3 million in 2023.
  • Biggest YoY gain for Non-Current Deferred Tax Liability was 139.5% in 2025; the steepest drop was 20.27% in 2025.
  • Year by year, Non-Current Deferred Tax Liability stood at $2.6 million in 2021, then dropped by 11.03% to $2.3 million in 2022, then soared by 86.14% to $4.3 million in 2023, then increased by 3.55% to $4.5 million in 2024, then soared by 139.5% to $10.8 million in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for OPRX at $10.8 million in Q4 2025, $4.5 million in Q3 2025, and $3.5 million in Q2 2025.